Alnylam Shares Climb on Surprising Earnings and Analyst Upgrades as Trading Volume Ranks 331st

Alnylam Pharmaceuticals (ALNY) closed 1.40% higher on August 15, 2025, with a trading volume of $320 million, a 42.51% drop from the previous day, ranking it 331st in market activity. The stock reached an all-time high of $445.44 earlier in the session, driven by strong earnings performance and analyst upgrades. Second-quarter results showed adjusted earnings of $0.32 per share, far outpacing expectations, alongside $773.7 million in revenue—a 64% year-over-year increase. This growth was primarily fueled by Amvuttra’s success in treating ATTR cardiomyopathy, which generated $150 million in its first full quarter, surpassing forecasts.

Analyst sentiment has turned bullish following the results. Oppenheimer upgraded Alnylam to Outperform, citing Amvuttra’s outperformance, while Wolfe Research raised its rating to Peerperform, highlighting the company’s robust patient acquisition capabilities. Despite current valuations appearing stretched with a wide analyst price target range of $236–$570, the stock’s 5.01% revenue growth and 83.64% gross margin underscore its financial resilience. Thirteen analysts have recently revised earnings estimates upward, reflecting confidence in the firm’s near-term profitability.

The strategy of buying the top 500 stocks by daily trading volume and holding them for one day from 2022 to present yielded a 1-day return of 0.98% and a total return of 31.52% over 365 days. This suggests the approach captured short-term momentum but also exposed investors to market volatility and timing risks, as demonstrated by the strategy’s mixed performance over the period.